Honestly, that's my motivation for following all of this. I'm in for a long haul. If the company is successful with FX-322, that makes them more likely to be successful with nerve regeneration. Otonomy gives me some hope for synapses. Hough Ear Institute is a little iffy, but with real promising science. Sound Pharmaceuticals' SPI-1005 seems really promising and with the added incentive of helping a global pandemic. Rinri Therapeutics seems like the real deal, but with a difficult project at hand.
Then you figure the FX-322 delivery is probably further along than we realize. Frequency Therapeutics is super professional and conservative with their claims.
Really, in 10 years, we could be looking at hair cells, synapses, nerves, inflammation, and noise trauma interventions all covered. Certainly, lots of action within 20 years.
Obviously, 20 years is a long way to wait. However, my hope is that as more drugs hit the market, the capacity to cope keeps improving.